INKT | MiNK Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	N/A - N/A
52 Week Range	N/A - N/A
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	N/A
Average Volume	N/A
Shares Outstanding	N/A
Market Cap	N/A
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-10-15

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	N/A
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	31
Country	USA
Website	INKT

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

INKT's peers: ADAP, ATNM, BYSI, AFMD, IMGN, SGMO, DAWN, ABOS, XFOR, INZY, VECT, TERN, HOOK, KA, CADL, FBRX, ALVR, GLUE, DSGN, HOWL, IKNA, STOK, MNKD, TCRT

*Chart delayed

Analyzing fundamentals for INKT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is very poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see INKT Fundamentals page.

Watching at INKT technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on INKT Technicals page.